| Leishmaniasis vaccine: where are we today? L Kedzierski Journal of global infectious diseases 2 (2), 177-185, 2010 | 280 | 2010 |
| Leishmania vaccines: progress and problems L Kedzierski, Y Zhu, E Handman Parasitology 133 (S2), S87-S112, 2006 | 266 | 2006 |
| Leishmaniasis: current treatment and prospects for new drugs and vaccines L Kedzierski, A Sakthianandeswaren, JM Curtis, PC Andrews, PC Junk, ... Current medicinal chemistry 16 (5), 599-614, 2009 | 230 | 2009 |
| Flavivirus receptors: diversity, identity, and cell entry M Laureti, D Narayanan, J Rodriguez-Andres, JK Fazakerley, ... Frontiers in immunology 9, 2180, 2018 | 217 | 2018 |
| Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses S Gras, L Kedzierski, SA Valkenburg, K Laurie, YC Liu, JT Denholm, ... Proceedings of the National Academy of Sciences 107 (28), 12599-12604, 2010 | 195 | 2010 |
| Integrated immune dynamics define correlates of COVID-19 severity and antibody responses M Koutsakos, LC Rowntree, L Hensen, BY Chua, CE Van De Sandt, ... Cell Reports Medicine 2 (3), 2021 | 154 | 2021 |
| Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection RJ Farr, CL Rootes, LC Rowntree, THO Nguyen, L Hensen, L Kedzierski, ... PLoS pathogens 17 (7), e1009759, 2021 | 148 | 2021 |
| Vaccines for the leishmaniases: proposals for a research agenda Working Group on Research Priorities for Development of Leishmaniasis Vaccines PLoS neglected tropical diseases 5 (3), e943, 2011 | 135 | 2011 |
| CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity THO Nguyen, LC Rowntree, J Petersen, BY Chua, L Hensen, L Kedzierski, ... Immunity 54 (5), 1066-1082. e5, 2021 | 134 | 2021 |
| Clonally diverse CD38+ HLA-DR+ CD8+ T cells persist during fatal H7N9 disease Z Wang, L Zhu, THO Nguyen, Y Wan, S Sant, SM Quiñones-Parra, ... Nature communications 9 (1), 1-12, 2018 | 125 | 2018 |
| Anti-leishmanial activity of heteroleptic organometallic Sb (V) compounds MI Ali, MK Rauf, A Badshah, I Kumar, CM Forsyth, PC Junk, L Kedzierski, ... Dalton Transactions 42 (48), 16733-16741, 2013 | 122 | 2013 |
| Development of vaccines against visceral leishmaniasis KJ Evans, L Kedzierski Journal of tropical medicine 2012 (1), 892817, 2012 | 114 | 2012 |
| Recent advances in antileishmanial drug development. AJ Davis, L Kedzierski Current opinion in investigational drugs (London, England: 2000) 6 (2), 163-169, 2005 | 110 | 2005 |
| A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3 L Kedzierski, J Montgomery, D Bullen, J Curtis, E Gardiner, ... The Journal of Immunology 172 (8), 4902-4906, 2004 | 108 | 2004 |
| The SPRY domain–containing SOCS box protein SPSB2 targets iNOS for proteasomal degradation Z Kuang, RS Lewis, JM Curtis, Y Zhan, BM Saunders, JJ Babon, ... Journal of Cell Biology 190 (1), 129-141, 2010 | 107 | 2010 |
| In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes L Kedzierski, JM Curtis, M Kaminska, J Jodynis-Liebert, M Murias Parasitology Research 102, 91-97, 2007 | 104 | 2007 |
| RIPLET, and not TRIM25, is required for endogenous RIG‐I‐dependent antiviral responses TJ Hayman, AC Hsu, TB Kolesnik, LF Dagley, J Willemsen, MD Tate, ... Immunology and cell biology 97 (9), 840-852, 2019 | 102 | 2019 |
| Leucine-rich repeats in host-pathogen interactions Ł Kędzierski, J Montgomery, J Curtis, E Handman Arch Immunol Ther Exp 52, 104-112, 2004 | 102 | 2004 |
| Immune responses during cutaneous and visceral leishmaniasis L Kedzierski, KJ Evans Parasitology 141 (12), 1544-1562, 2014 | 85 | 2014 |
| Suppressor of cytokine signaling 4 (SOCS4) protects against severe cytokine storm and enhances viral clearance during influenza infection L Kedzierski, EM Linossi, TB Kolesnik, EB Day, NL Bird, BT Kile, GT Belz, ... PLoS pathogens 10 (5), e1004134, 2014 | 76 | 2014 |
